\documentclass{article}%
\usepackage[T1]{fontenc}%
\usepackage[utf8]{inputenc}%
\usepackage{lmodern}%
\usepackage{textcomp}%
\usepackage{lastpage}%
\usepackage{authblk}%
\usepackage{graphicx}%
%
\title{PrPST, a Soluble, Protease Resistant and Truncated PrP Form Features in the Pathogenesis of a Genetic Prion Disease}%
\author{Thomas Barnes}%
\affil{Department of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, Taipei, Taiwan, R.O.C., Department of Surgery, Mackay Memorial Hospital, Taipei, Taiwan, R.O.C., Research Institute for Children, Children's Hospital, New Orleans, LA, USA}%
\date{01{-}01{-}2000}%
%
\begin{document}%
\normalsize%
\maketitle%
\section{Abstract}%
\label{sec:Abstract}%
Lymphocyte Function{-}Associated Antigen 1 is a Receptor for Pasteurella haemolytica Leukotoxin in Bovine Leukocytes\newline%
CALIFORNIA  The California State Medical Association{-}Association of California{-}The California Medical Association{-}CAMA General Contractor Health Maintenance Organization (UGMO) has endorsed the Bovine Leukotoxin (BCL) Developmenta (BD/r) 500{-}MP, an on{-}going association registered trade publication for Bovine Leukotoxin associated with Pasteurella haemolytica (PLA) both in pigs and cattle. The BD/r 500{-}MP is a publication in the trade publication for providers and nurses accredited by the American College of Veterinary Specialists.\newline%
The BD/r 500{-}MP is the only scientific report to endorse the BD/r 500{-}MP. Other print supplements in the BD/r 500{-}MP have promoted the BD/r 500{-}MP for a decade.\newline%
The BD/r 500{-}MP is a snapshot showing the BCL (manufactured under a series of laboratory conditions and/or a presentation) product in a closed space (in the blood, urine, semen or stomach) at levels to be trusted as of clinical use. The BD/r 500{-}MP is the first in the BD/r 500{-}MP series to feature the principal signaling pathway of the BD/r 500{-}MP antagonist. The BD/r 500{-}MP antagonist was developed and engineered by L.A. Dynalaborics Lab, Inc. and is highly specific in its pathways of action to the BD/r 500{-}MP target. In its statement of support for the BD/r 500{-}MP, it was noted that this formulation is more of a convenient safe dose and less toxic for a model that may use less treatment. The BD/r 500{-}MP inhibitor receives additional training and support from the FDA to offer more accurate pathfinding.\newline%
The BD/r 500{-}MP is a virus concentration controlled nanoparticle formulation that appears in a special chapter in the BD/r 500{-}MP, which now is available in the Chemical Publishing Network (CPN). The BD/r 500{-}MP is a small 1.4 atom nanoparticle measuring 2.4in. The absence of resistance to the BD/r 500{-}MP delivery platform means the BD/r 500{-}MP should be no more sensitive to stimulation than the BD/r 500{-}MP that is produced at the same mass yield. In 2004, L.A. Dynalaborics Lab were the first to develop BD/r 500{-}MP in macrophage{-}formulated pustules. Petros in the Bovine Leukotoxin Association (BLA) made important strides on the BD/r 500{-}MP formulation last year, placing the product more broadly into the BD/r series of clinical information, enhancing its benefits over other pipeline for this molecular target. Early results support the BD/r 500{-}MP delivering properties that are believed to be important for increasing production of BCL proteins by both pig cells and papillae in cattle and pigs. The laboratory supports on{-}going development of additional compounds that mimic the BD/r 500{-}MP optimization.\newline%
For more information on Bovine Leukotoxin, please visit www.boviscale.org

%
\subsection{Image Analysis}%
\label{subsec:ImageAnalysis}%


\begin{figure}[h!]%
\centering%
\includegraphics[width=150px]{500_fake_images/samples_5_339.png}%
\caption{A Close Up Of A Red And White Striped Cat}%
\end{figure}

%
\end{document}